poisar

Stock

Disc Medicine, Inc. IRON

$78.38-2.04%

Overview

IRON market data

Price History

IRON price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$6.01
Diluted earnings per share over the trailing twelve months.
Beta
0.90
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$40.00 – $99.50
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $3.1B · P/B 4.05.

Company News

7 captured
HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $120Benzinga · Aug 6, 2026, 10:21 AM
Disc Medicine Q2 EPS $(1.54) Beats $(1.77) EstimateBenzinga · Jul 30, 2026, 12:36 PM
8-K filing — Disc Medicine, Inc. (IRON)SEC EDGAR · Jul 30, 2026, 12:32 PM
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $85Benzinga · Jun 16, 2026, 1:35 PM
Disc Medicine Completes FDA Type A Meeting Regarding The Complete Response Letter To The New Drug Application For Bitopertin In Erythropoietic Protoporphyria; Data From APOLLO Phase 3 Study Expected In Q4 2026Benzinga · Jun 9, 2026, 12:40 PM
Disc Medicine Presents Updated Data From Myelofibrosis And Anemia Treatment RALLY-MF Phase 2 Trial Showing Reductions In Hepcidin And Higher Iron Levels, A Positive Clinical Impact On Anemia Measures Across A Broad Range Of Patient TypesBenzinga · Jun 2, 2026, 12:07 PM
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $80Benzinga · May 14, 2026, 5:00 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock